Literature DB >> 21411784

The prognostic impact of sex on surgically resected non-small cell lung cancer depends on clinicopathologic characteristics.

William Sterlacci1, Alexandar Tzankov, Lothar Veits, Wilhelm Oberaigner, Thomas Schmid, Wolfgang Hilbe, Michael Fiegl.   

Abstract

The increasing incidence of lung cancer in women and their supposed survival advantage over men requires clarification of the significance of sex. Age, stage, histologic features, differentiation grade, and Ki-67 index were assessed in 405 surgically resected non-small cell lung cancers (NSCLCs) using a standardized tissue microarray platform. Women were associated with well/moderate tumor differentiation, a Ki-67 index of 3% or less, and adenocarcinoma histologic features. Female sex predicted increased survival time only by univariate analysis. Stratified by sex, increased survival was noted for women older than 64 years, with a tumor at postsurgical International Union Against Cancer stage I, with adenocarcinoma histologic features, with well- or moderately differentiated tumors, or with a Ki-67 index of 3% or less. Sex is not an independent prognostic parameter for patients with surgically resected NSCLC. Sex-linked differences are associated with other factors, thus simulating a prognostic impact of sex. This study elucidates sex-specific interactions between patient and tumor characteristics, which are pivotal toward improving prognostic accuracy, individualized therapies, and screening efforts.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21411784     DOI: 10.1309/AJCPQF24NYWNMVMG

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  Detailed assessment of microvasculature markers in non-small cell lung cancer reveals potentially clinically relevant characteristics.

Authors:  Geoffrey Pomme; Florian Augustin; Michael Fiegl; Raoul A Droeser; William Sterlacci; Alexandar Tzankov
Journal:  Virchows Arch       Date:  2015-04-09       Impact factor: 4.064

2.  Evaluation of lung cancer by enhanced dual-energy CT: association between three-dimensional iodine concentration and tumour differentiation.

Authors:  Shingo Iwano; Rintaro Ito; Hiroyasu Umakoshi; Shinji Ito; Shinji Naganawa
Journal:  Br J Radiol       Date:  2015-09-02       Impact factor: 3.039

3.  Expression of the CXCR4 ligand SDF-1/CXCL12 is prognostically important for adenocarcinoma and large cell carcinoma of the lung.

Authors:  William Sterlacci; Shereen Saker; Bettina Huber; Michael Fiegl; Alexandar Tzankov
Journal:  Virchows Arch       Date:  2016-01-27       Impact factor: 4.064

4.  Are comorbidities associated with long-term survival of lung cancer? A population-based cohort study from French cancer registries.

Authors:  A Seigneurin; P Delafosse; B Trétarre; A S Woronoff; M Velten; P Grosclaude; A V Guizard; B Lapôtre-Ledoux; S Bara; F Molinié; M Colonna
Journal:  BMC Cancer       Date:  2018-11-12       Impact factor: 4.430

5.  Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Authors:  Haiyan Zeng; Danyang Zheng; Willem J A Witlox; Antonin Levy; Alberto Traverso; Feng-Ming Spring Kong; Ruud Houben; Dirk K M De Ruysscher; Lizza E L Hendriks
Journal:  Front Oncol       Date:  2022-06-10       Impact factor: 5.738

6.  Quality of life after the initial treatments of non-small cell lung cancer: a persistent predictor for patients' survival.

Authors:  Irawati Lemonnier; Francis Guillemin; Patrick Arveux; Christelle Clément-Duchêne; Michel Velten; Marie-Christine Woronoff-Lemsi; Damien Jolly; Cédric Baumann
Journal:  Health Qual Life Outcomes       Date:  2014-05-15       Impact factor: 3.186

7.  Augmented expression of Ki-67 is correlated with clinicopathological characteristics and prognosis for lung cancer patients: an up-dated systematic review and meta-analysis with 108 studies and 14,732 patients.

Authors:  Dan-Ming Wei; Wen-Jie Chen; Rong-Mei Meng; Na Zhao; Xiang-Yu Zhang; Dan-Yu Liao; Gang Chen
Journal:  Respir Res       Date:  2018-08-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.